New Zealand markets close in 2 hours 42 minutes

Roivant Sciences Ltd. (ROIV)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
4.4600+0.2500 (+5.94%)
At close: 04:00PM EDT
4.6800 +0.22 (+4.93%)
After hours: 06:03PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close4.2100
Bid4.4400 x 2900
Ask4.8000 x 800
Day's range4.1700 - 4.4900
52-week range2.5200 - 16.7600
Avg. volume1,044,595
Market cap3.136B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Roivant Sciences to Report Financial Results for the Quarter Ended June 30, 2022 on Monday, August 15, 2022

    Investor call and webcast scheduled for Monday, August 15 at 8:00 a.m. EDTRoivant will host an investor day on Wednesday, September 28 at 11:00 a.m. EDT BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV), a biopharmaceutical company dedicated to improving the delivery of healthcare to patients, today announced that it will host a live conference call and webcast at 8:00 a.m. EDT on Monday, August 15, 2022 to report its financi

  • GlobeNewswire

    Roivant Sciences Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 and Provides Business Update

    Potential blockbuster VTAMA® (tapinarof) approved by FDA for the treatment of plaque psoriasis at end of May 2022 is the first topical novel chemical entity launched for plaque psoriasis in 25 years; product and samples are now available across the US, a robust patient support program is in place and a 100+ person commercial organization is fully deployed to target 4 million potential annual topical psoriasis prescriptions in the USEnrollment in the VTAMA registrational trials for atopic dermati

  • GlobeNewswire

    Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus

    Brepocitinib is a potential first-in-class dual, selective inhibitor of TYK2 and JAK1; in all five placebo-controlled studies completed to date, oral brepocitinib generated statistically significant and clinically meaningful resultsPriovant is developing brepocitinib in severe autoimmune diseases with few approved therapies and where dual inhibition of TYK2 and JAK1 may provide greater efficacy than inhibiting either aloneA single registrational Phase 3 trial evaluating oral brepocitinib in derm